Shorla Oncology is attending AXS25 SUMMIT April 27 - May 1, 2025 - Shorla Oncology: A Leader in Innovative Oncology Solutions

Shorla Oncology is proud to be attending AXS25 Summit in Las Vegas, April 27 – May 1, 2025!

AXS25 Summit brings together thousands of pharmacy and pharmaceutical industry leaders to collaborate, connect, and define the future of patient access, prescription fulfillment, and drug delivery.

Let’s connect!

Shorla Oncology is attending AXS25 SUMMIT April 27 – May 1, 2025

FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers

Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available

Tepylute for breast, ovarian cancer launched in US

Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

Shorla wins FDA nod for ready-to-dilute Tepylute

Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available

FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG

FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG

LATEST NEWS